skip to content
 
Dr John Liddicoat's picture

Email

jel68@cam.ac.uk

Faculty Contact Details

Room: Room 319 (ARB)

Tel: 01223330088


PhD, BSc (Hons), LLB (Hons)
Senior Research Associate

Interests

Intellectual property; patent law; patent practice; patent strategy; commercialisation; translational research; copyright; confidential information; biotechnology; pharmaceuticals; diagnostics; drug repurposing; precision medicine; 3D printers; regulation of innovation; regulation of information; empirical research; doctrinal research

CV / Biography

I am broadly interested in the development and use of new technology as it has the ability to: drive economies forward, increase public welfare and resolve important social problems. Much of my research focuses on the ability of patent law to meet its welfare-enhancing goal of accelerating the creation of new technology. In biotechnology and life-sciences — special interests of mine — this focus is particularly important, but it is also complicated; although patents can operate as incentives, they have numerous trade-offs. Smart innovation policy requires meticulous, transnational doctrinal research and robust empirical data. As a lawyer with scientific training, I strive to deliver both.

In 2018, Dr Kathy Liddell, Professor Mateo Aboy and I finished a project titled ‘Realising Genomic Medicine: Intellectual Property Issues Beyond the “Old” DNA Patent Debates’. See here for more detail.

We are now working on a project investigating the legal incentives surrounding the development of new uses for known drugs, commonly known as drug repurposing, a field of research in which scientists develop new medical uses for known drugs. Developing repurposed drugs is often quicker, cheaper and more likely to receive government authorisation than developing new drugs (from discovery), predominantly because much is already known about repurposed drugs’ safety and effectiveness. Consequently, they are an attractive proposition for both governments and drug companies in societies that desire new treatments at low prices. 

Despite the attractions of repurposing drugs, many experts argue that too few drugs are repurposed. A key reason for this shortfall, they argue, is that the law fails to sufficiently incentivise them. As a result, they suggest, amongst other things, that patent law and/or regulatory exclusivities should be amended to remedy the situation. Perhaps unsurprisingly, other experts oppose these arguments, insisting that the suggested amendments would have the opposite effect, raising drug prices and reducing treatment options.

This research project aims to inform and resolve this debate through novel doctrinal research and innovative empirical methods.

The project is part of the wider CeBIL research programme, and we work closely with our collaborators in Copenhagen, Harvard and Michigan.

Publications

 

Books

"The Innovation Pool in Biotechnology: The Role of Patents in Facilitating Innovation"

Co-Author/s:
Nicol, D, Nielsen, J, Critchley, C, Whitton, T,
Published:
Aug 2014
ISBN:
1445-­2766

Articles

"The Effects of Myriad and Mayo on Molecular Test Development in the US and Europe: Interviews from the Frontline" (forthcoming 2020) Vanderbilt Journal of Entertainment and Technology Law

Co-Author/s:
Kathy Liddell and Mateo Aboy
Citation:
(forthcoming 2020) Vanderbilt Journal of Entertainment and Technology Law
Published:
Feb 2020

"How does emerging patent case law in the US and Europe affect precision medicine?" Forthcoming, Nature Biotechnology

Co-Author/s:
M. Aboy, K Liddell, C Crespo, I G Cohen, S Gerke & T Minssen
Citation:
Forthcoming, Nature Biotechnology
Published:
Jan 2020

"International Divergence in Gene Patenting" (2019) 20 Annual Review of Genomics and Human Genetics 1

Co-Author/s:
Nicol, D., Dreyfuss, R., Gold, E., Li, W. & Van Overwalle, G.
Citation:
(2019) 20 Annual Review of Genomics and Human Genetics 1
Published:
Aug 2019

"Mayo’s impact on patent applications related to biotech, diagnostics, and personalized medicine?" (2019) 37(5) Nature Biotechnology 513

Co-Author/s:
Aboy, M., Crespo, C., Liddell, K., & Minssen, T.
Citation:
(2019) 37(5) Nature Biotechnology 513
Published:
Feb 2019

"Continental Drift? Do European Clinical Genetics Laboratories have a Patent Problem?" (2019) 27 European Journal of Human Genetics 997

Co-Author/s:
Liddell, K., McCarthy, A., Hogarth, S., Aboy, M., Nicol, D., Patton S. and Hopkins M.
Citation:
(2019) 27 European Journal of Human Genetics 997
Published:
Feb 2019

"Was the Myriad Decision a ‘Surgical Strike on Isolated DNA Patents, or Does it Have Wider Impacts?" (2018) 36(12) Nature Biotechnology 1146

Co-Author/s:
Aboy, M., Crespo, C., Liddell, K. & Jordan, M.
Citation:
(2018) 36(12) Nature Biotechnology 1146
Published:
Dec 2018

"Provenance and Risk in Transfer of Biological Materials" (13 August 2018) PLOS Biology

Co-Author/s:
Jane Nielsen, Tania Bubela, Don R. C. Chalmers, Amber Johns, Linda Kahl, Joanne Kamens, Charles Lawson, Rebekah McWhirter, Ann Monotti, James Scheibner, Tess Whitton, & Dianne Nicol
Citation:
(13 August 2018) PLOS Biology
Published:
Aug 2018

"Divided Performance of Patented Methods in Australia: A Call to Codify Procured Infringement" (2018) 41(1) University of New South Wales Law Review 252

Citation:
(2018) 41(1) University of New South Wales Law Review 252
Published:
Jan 2018

"After Myriad, what makes a gene patent claim 'markedly different' from nature?" (2017) 35 Nature Biotechnology 820

Co-Author/s:
Aboy, M., Liddell, K., Jordan, M., Crespo, C.
Citation:
(2017) 35 Nature Biotechnology 820
Published:
Sep 2017
DOI:
doi:10.1038/nbt.3953

"Key Challenges in Bringing CRISPR-Mediated Somatic Cell Therapy into the Clinic" (2017) 9 Genome Medicine 85

Co-Author/s:
Nicol, D., Eckstein, E., Morrison, M., Sherkow, J.S.,Otlowski, M., Whitton, T., Bubela, T., Burdon, K.P., Chalmers, D., Chan, S., Charlesworth, J., Critchley, C., Crossley, M., de Lacey, S., Dickinson, J.L., Hewitt, A.W., Kamens, J., Kato, K.,
Citation:
(2017) 9 Genome Medicine 85
Published:
Sep 2017
DOI:
https://doi.org/10.1186/s13073-017-0475-4

"Standing on the Edge – What Type of “Exclusive Licensees” Should be Able to Initiate Patent Infringement Actions?" (2017) 48 IIC - International Review of Intellectual Property and Competition Law 626

Citation:
(2017) 48 IIC - International Review of Intellectual Property and Competition Law 626
Published:
Aug 2017
DOI:
DOI 10.1007/s40319-017-0620-z

"The Multiple Dimensions of Intellectual Property Infringement in the 3D Printing Era" (2017) 27 Australian Intellectual Property Journal 184

Co-Author/s:
Nielsen, J.L.
Citation:
(2017) 27 Australian Intellectual Property Journal 184
Published:
Jun 2017

"Myriad's Impact on Gene Patents" (2016) 34 Nature Biotechnology 1119

Co-Author/s:
Aboy, M., Liddell, K., Crespo, C.
Citation:
(2016) 34 Nature Biotechnology 1119
Published:
Nov 2016
DOI:
doi:10.1038/nbt.3719

"The Examination Effect: A Comparison of the Outcome of Patent Examination in the US, Europe and Australia" (2016) 16 John Marshall Review of Intellectual Property Law 21

Co-Author/s:
Christie, A.F., Dent, C.
Citation:
(2016) 16 John Marshall Review of Intellectual Property Law 21
Published:
Nov 2016

"Precision Medicine: Drowning in Regulatory Soup?" (2016) 3(2) Journal of Law and the Biosciences 281

Co-Author/s:
Nicol et al
Citation:
(2016) 3(2) Journal of Law and the Biosciences 281
Published:
Aug 2016

"Three Dimensions of Patent Infringement: Liability for Creation and Distribution of CAD Files" (2016) 26 Australian Intellectual Property Journal 165

Co-Author/s:
Nielsen, J, Nicol, D
Citation:
(2016) 26 Australian Intellectual Property Journal 165
Published:
May 2016

"Reluctance Realised? Emerging Problems with s 117(2)(b) Patents Act 1990 (Cth)" (2015) 41 Monash Law Review 163

Citation:
(2015) 41 Monash Law Review 163
Published:
Nov 2015

"Are the Gene-Patent Storm Clouds Dissipating? A Global Snapshot" (2015) 33(4) Nature Biotechnology 347

Co-Author/s:
Whitton, T, Nicol D
Citation:
(2015) 33(4) Nature Biotechnology 347
Published:
Apr 2015

"Another Missed Opportunity to Reform Use of Patents Without Authorisation in Australia" (2014) 25 Australian Intellectual Property Journal 74

Co-Author/s:
Nielsen, J, Nicol, D, Whitton, T
Citation:
(2014) 25 Australian Intellectual Property Journal 74
Published:
Aug 2014

"Re-Evaluating Innocent Infringement in Australia: Patent Numbers and Virtual Marking" (2014) 25 Australian Intellectual Property Journal 18

Citation:
(2014) 25 Australian Intellectual Property Journal 18
Published:
Aug 2014

"Sharing the Burden in Australian Drug Discovery and Development: Collaborative Trends in Translational Research" (2014) 3 Intellectual Property Quarterly 181

Co-Author/s:
Nielsen, J, Nicol, D, Whitton, T
Citation:
(2014) 3 Intellectual Property Quarterly 181
Published:
Aug 2014

"Time to Get Serious About Privacy Policies: the Special Case of Genetic Privacy" (2014) 42 Federal Law Review 149

Co-Author/s:
Nicol, D, Hagger MC
Citation:
(2014) 42 Federal Law Review 149
Published:
Aug 2014

"Re-evaluating False Patent Marking in Australia" (2013) 22(2) Journal of Law, Information and Science 128

Co-Author/s:
Nicol, D
Citation:
(2013) 22(2) Journal of Law, Information and Science 128
Published:
Aug 2013

"Do patents impede the provision of genetic tests in Australia?" (2013) 37 Australian Health Review 281

Co-Author/s:
Nicol, D
Citation:
(2013) 37 Australian Health Review 281
Published:
Aug 2013

"A role for Virtual Biotechnology Companies in Drug Discovery and Development?" (2013) 19 Journal of Commercial Biotechnology 10

Co-Author/s:
Nicol, D
Citation:
(2013) 19 Journal of Commercial Biotechnology 10
Published:
Aug 2013

"Legislating to Exclude Gene Patents: Difficult and Unhelpful, or Useful and Feasible?" (2012) 22(1) Journal of Law and Information Science 32

Co-Author/s:
Nicol, D
Citation:
(2012) 22(1) Journal of Law and Information Science 32
Published:
Aug 2012

Book Chapters

"IP Policies for Large Bioresources: the Fiction, Fantasy and Future of Openness", Global Genes. Local Concerns (Edward Elgar)

Publisher:
Edward Elgar
Published Date:
Apr 2019

"Australia", Balancing Copyright - A Survey of National Approaches (Springer-Verlag)

Publisher:
Springer-Verlag
Published Date:
Aug 2012
ISBN 13:
978-3-642-29596-6

Book Reviews

Review of Michele Boldrin and David Levine's 'Against Intellectual Monopoly' (2011) 21 Journal of Law, Information & Science

Published:
Apr 2011

Case Notes

When can “exclusive” licensees initiate patent infringement proceedings? Lessons for global IP licensing transactions from two recent UK cases (2019) 14(1) Journal of Intellectual Property Law & Practice 2

Co-Author/s:
de Werra, J
Published:
Feb 2019

United Kingdom patent decisions 2017 (2018) 49 International Review of Intellectual Property and Competition Law 318

Co-Author/s:
Julia Powles
Published:
Feb 2018

Reports

Precision Medicine: Legal and Ethical Challenges

Co-Author/s:
Skopek, J., Liddell, K.
Published:
Aug 2017
Body / Institution:
University of Cambridge

Open Innovation with Large Bioresources: Goals, Challenges and Proposals

Co-Author/s:
Liddell, K.
Published:
Dec 2016
Reference Number:
University of Cambridge Faculty of Law Research Paper No. 6/2017
Body / Institution:
University of Cambridge